Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT03872180 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

CCND1 Positive
Mantle Cell Lymphoma
t(11;14) Positive

Interventions

DRUG: Bendamustine
BIOLOGICAL: Obinutuzumab
DRUG: Venetoclax

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]